Michael Resl
-
- Heart Failure Treatment and Management 14
- Cardiovascular Function and Risk Factors 10
- Rheumatology top 5%
- GDF15 and Related Biomarkers 5
-
- Diabetes Treatment and Management 18
- Diabetes Management and Research 8
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 6
- Physiology top 10%
-
- Diabetes and associated disorders 7
-
- Metabolism, Diabetes, and Cancer 5
In The Last Decade
Michael Resl
49 papers receiving 871 citations
Peers
Comparison fields: 5 of 90
- Cardiology and Cardiovascular Medicine 462
- Rheumatology 212
- Endocrinology, Diabetes and Metabolism 219
- Physiology 209
- Biological Psychiatry 17
Countries citing papers authored by Michael Resl
This map shows the geographic impact of Michael Resl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Resl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Resl more than expected).
Fields of papers citing papers by Michael Resl
This network shows the impact of papers produced by Michael Resl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Resl. The network helps show where Michael Resl may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Resl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2023 | 4 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 4 | |
| 5 | 2022 | 3 | |
| 6 | 2022 | 4 | |
| 7 | 2021 | 26 | |
| 8 | 2021 | 4 | |
| 9 | 2021 | 7 | |
| 10 | 2019 | 12 | |
| 11 | 2019 | 1 | |
| 12 | 2019 | 3 | |
| 13 | 2019 | 1 | |
| 14 | 2016 | 32 | |
| 15 | 2013 | 4 | |
| 16 | 2013 | 212 | |
| 17 | 2012 | 49 | |
| 18 | 2011 | 21 | |
| 19 | 2011 | 17 | |
| 20 | 2009 | 2 |
About Michael Resl
Michael Resl is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Behavioral Neuroscience, having authored 53 papers that have together received 885 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (18 papers), Heart Failure Treatment and Management (14 papers), Cardiovascular Function and Risk Factors (10 papers), Diabetes Management and Research (8 papers), Diabetes and associated disorders (7 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (6 papers), GDF15 and Related Biomarkers (5 papers) and Metabolism, Diabetes, and Cancer (5 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (462 citations), Rheumatology (212 citations) and Endocrinology, Diabetes and Metabolism (219 citations). Michael Resl has collaborated with scholars based in Austria, Germany and Australia. Frequent co-authors include Martin Clodi, Anton Luger, Greisa Vila, Richard Pacher, Stephanie Neuhold, Guido Strunk, Rudolf Prager, Michaela Riedl, Christopher Adlbrecht and Martin Hülsmann. Their work appears in journals such as Journal of Applied Physiology, Clinical Chemistry, Heart, Wiener klinische Wochenschrift and Journal of Hypertension.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.